FREMONT, Calif., November 8, 2023 – Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that its Cytek^® Aurora™ CS system has been selected as the “Cell Sorting Product of the Year” in the third annual BioTech Breakthrough Awards program. This program is conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. This year’s program attracted more than 1,500 nominations from 12 different countries.

The Cytek Aurora CS system is the only cell sorter on the market that offers the unique ability to combine the advantages of Full Spectrum Profiling™ (FSP™) technology with high-performance cell sorting. The Cytek Aurora CS system is built on the same FSP technology as the Cytek Aurora cell analysis system, which allows seamless transfer of assays between systems without redesigning panels, reconfiguring detectors, or sacrificing resolution.

FSP technology is a novel approach that detects the full spectrum of the fluorescent probes labeled on each cell, facilitating the resolution of the most challenging cell populations, such as cells with high autofluorescence, low levels of biomarker expression or rare populations – regardless of assay size and complexity, with the ability to accurately sort subpopulations for high dimensional and high complexity applications. Combining the benefits of FSP technology with a customizable sorting platform provides scientists with increased flexibility in panel design, simplifies workflow with single-tube assays, and delivers high-resolution sorting capability at the single cell level. The Cytek Aurora CS system enables scientists to gain a deeper understanding of complex biological systems.

“We’re thrilled to present Cytek Biosciences with the ‘Cell Sorting Product of the Year’ award,” said Bryan Vaughn, managing director of BioTech Breakthrough Awards. “Their technology addresses the difficulty of sorting challenging cell populations. The Cytek Aurora CS system is able to multiplex, resolve and isolate even the dim and rarest populations, therefore, scientists can now push the boundaries of their research and make new discoveries.”

The mission of the annual BioTech Breakthrough Awards program is to conduct the most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today.

“Utilizing our powerful FSP technology, we set out to develop a solution that can accommodate a variety of biological and sorting conditions, while allowing researchers to confidently and efficiently isolate populations of interest for downstream applications,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. “We are proud to accept this award from BioTech Breakthrough, and will continue to build on our successes that advance the next generation of cell analysis solutions.”

Please visit www.cytekbio.com for more information.

About Cytek Biosciences, Inc.

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora™ CS; the flow cytometer and imaging products under the Amnis^® and Guava^® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding Cytek’s business plans, including continuing to build on its successes that advance the next generation of cell analysis solutions. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to Cytek’s ability to manage the growth and complexity of its organization; Cytek’s ability to manage relationships with key customers and suppliers; Cytek’s ability to retain key employees; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; global economic and market conditions; competition; and Cytek’s  dependence on certain sole and single source suppliers. You should refer to the section entitled “Risk Factors” set forth in Cytek’s most recent Quarterly Report on Form 10-Q filed with the SEC and other filings Cytek Biosciences makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release.

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com

Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com

# # #